BIOA BioAge Labs
- 4.300
- +0.200+4.88%
- 4.428
- +0.128+2.99%
BioAge Labs News
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
BioAge Stock Advances 14% On Novartis Research Collaboration
BioAge Labs Says It Is Partnering With Novartis to Identify Drug Targets to Treat Age-Related Diseases
Express News | Bioage Labs Inc - May Receive up to $530M in Future Milestones
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures - Hagens Berman
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More
Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday
Express News | Bioage Labs Falls 76.9% After Jefferies Cuts PT on Co
Traders Eye Key Inflation Report as US Equity Futures Waver Pre-Bell
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Express News | BioAdge Labs Shares Are Trading Lower After Jefferies Downgraded the Stock From Buy to Hold and Citigroup Downgraded the Stock From Buy to Neutral. Additionally, Both Firms Cut Their Price Target on the Stock to $7
Top Premarket Decliners
Just Two Months After IPO, BioAge Labs Stops Eli Lilly-Collaborated Obesity Trial On Safety Concerns
Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination With Tirzepatide for the Treatment of Obesity
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40
BioAge Shares Slide Premarket After Obesity Study Halted for Safety
Jefferies Downgrades Bioage Labs to Hold, Lowers Price Target to $7
Bioage Labs Analyst Ratings
No Data
